Wex Pharmaceuticals Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.wexinc.com/
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Phase 2
Terminated
- Conditions
- Chemotherapy-induced Neuropathic PainChemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05359133
- Locations
- 🇺🇸
Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸MEDSOL Clinical Research Center, Port Charlotte, Florida, United States
A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04083833
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Phase 2
Terminated
- Conditions
- PainPeripheral NeuropathyNeuropathic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01655823
- Locations
- 🇺🇸
Lalita Pandit, Fountain Valley, California, United States
🇺🇸Global Research Management, Los Angeles, California, United States
🇺🇸Innovative Clinical Research, Los Angeles, California, United States
Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01527734
- Locations
- 🇺🇸
Comprehensive Clinical Research, Tacoma, Washington, United States
Tetrodotoxin Open-label Efficacy and Safety Continuation Study
Phase 3
Completed
- Conditions
- PainCancer
- Interventions
- Biological: Tetrodotoxin
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT00726011
- Locations
- 🇨🇦
WEX Pharmaceuticals Inc., Vancouver, British Columbia, Canada
Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain
Phase 3
Completed
- Conditions
- PainCancer
- Interventions
- Biological: PlaceboBiological: Tetrodotoxin
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT00725114
- Locations
- 🇨🇦
WEX Pharmaceuticals Inc., Vancouver, British Columbia, Canada
© Copyright 2025. All Rights Reserved by MedPath